These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 29019161)
1. Assessing the Use of a Feedback Module to Model EQ-5D-5L Health States Values in Hong Kong. Wong ELY; Ramos-Goñi JM; Cheung AWL; Wong AYK; Rivero-Arias O Patient; 2018 Apr; 11(2):235-247. PubMed ID: 29019161 [TBL] [Abstract][Full Text] [Related]
2. Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study. Ludwig K; von der Schulenburg JG; Greiner W Health Qual Life Outcomes; 2017 Feb; 15(1):39. PubMed ID: 28219389 [TBL] [Abstract][Full Text] [Related]
3. Normative Profile of Health-Related Quality of Life for Hong Kong General Population Using Preference-Based Instrument EQ-5D-5L. Wong EL; Cheung AW; Wong AY; Xu RH; Ramos-Goñi JM; Rivero-Arias O Value Health; 2019 Aug; 22(8):916-924. PubMed ID: 31426933 [TBL] [Abstract][Full Text] [Related]
4. German Value Set for the EQ-5D-5L. Ludwig K; Graf von der Schulenburg JM; Greiner W Pharmacoeconomics; 2018 Jun; 36(6):663-674. PubMed ID: 29460066 [TBL] [Abstract][Full Text] [Related]
5. Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L. Hobbins A; Barry L; Kelleher D; Shah K; Devlin N; Goni JMR; O'Neill C Pharmacoeconomics; 2018 Nov; 36(11):1345-1353. PubMed ID: 30051267 [TBL] [Abstract][Full Text] [Related]
6. Does the Introduction of the Ranking Task in Valuation Studies Improve Data Quality and Reduce Inconsistencies? The Case of the EQ-5D-5L. Ramos-Goñi JM; Rand-Hendriksen K; Pinto-Prades JL Value Health; 2016 Jun; 19(4):478-86. PubMed ID: 27325340 [TBL] [Abstract][Full Text] [Related]
7. Test-Retest Reliability of EQ-5D-5L Valuation Techniques: The Composite Time Trade-Off and Discrete Choice Experiments. Purba FD; Hunfeld JAM; Timman R; Iskandarsyah A; Fitriana TS; Sadarjoen SS; Passchier J; Busschbach JJV Value Health; 2018 Oct; 21(10):1243-1249. PubMed ID: 30314626 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan. Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K Value Health; 2016; 19(5):648-54. PubMed ID: 27565282 [TBL] [Abstract][Full Text] [Related]
9. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set. Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730 [TBL] [Abstract][Full Text] [Related]
10. Handling Data Quality Issues to Estimate the Spanish EQ-5D-5L Value Set Using a Hybrid Interval Regression Approach. Ramos-Goñi JM; Craig BM; Oppe M; Ramallo-Fariña Y; Pinto-Prades JL; Luo N; Rivero-Arias O Value Health; 2018 May; 21(5):596-604. PubMed ID: 29753358 [TBL] [Abstract][Full Text] [Related]
11. Valuation of the EQ-5D-5L in Taiwan. Lin HW; Li CI; Lin FJ; Chang JY; Gau CS; Luo N; Pickard AS; Ramos Goñi JM; Tang CH; Hsu CN PLoS One; 2018; 13(12):e0209344. PubMed ID: 30586400 [TBL] [Abstract][Full Text] [Related]
12. United States Valuation of EQ-5D-5L Health States Using an International Protocol. Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935 [TBL] [Abstract][Full Text] [Related]
13. Determinants of time trade-off valuations for EQ-5D-5L health states: data from the Canadian EQ-5D-5L valuation study. Sayah FA; Bansback N; Bryan S; Ohinmaa A; Poissant L; Pullenayegum E; Xie F; Johnson JA Qual Life Res; 2016 Jul; 25(7):1679-85. PubMed ID: 26659899 [TBL] [Abstract][Full Text] [Related]
14. Valuing Health Using Time Trade-Off and Discrete Choice Experiment Methods: Does Dimension Order Impact on Health State Values? Mulhern B; Shah K; Janssen MF; Longworth L; Ibbotson R Value Health; 2016; 19(2):210-7. PubMed ID: 27021755 [TBL] [Abstract][Full Text] [Related]
15. Preparatory study for the revaluation of the EQ-5D tariff: methodology report. Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945 [TBL] [Abstract][Full Text] [Related]
16. Valuation of EQ-5D-5L in the Kingdom of Saudi Arabia: A National Representative Study. Al-Jedai A; Almudaiheem H; Al-Salamah T; Aldosari M; Almutairi AR; Almogbel Y; AlRuthia Y; Althemery AU; Alluhidan M; Roudijk B; Purba FD; Awad N; O'jeil R Value Health; 2024 May; 27(5):552-561. PubMed ID: 38342365 [TBL] [Abstract][Full Text] [Related]
17. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States. Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663 [TBL] [Abstract][Full Text] [Related]
18. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada. Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA; Med Care; 2016 Jan; 54(1):98-105. PubMed ID: 26492214 [TBL] [Abstract][Full Text] [Related]
19. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets. Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577 [TBL] [Abstract][Full Text] [Related]